Riders · Department of State Health Services · Article II: Health and Human Services

HIV Vendor Drug Rebate Funding Loss Replacement

Rider 37 in the House passed, page II-32

This rider is not in the Conference or any later version.

Through the session

  1. 2024-25 Act Not in this version
  2. Introduced (Senate) Not in this version
  3. Introduced (House) Not in this version
  4. Senate substitute Not in this version
  5. House substitute New rider 37
  6. House passed Unchanged rider 37
  7. Conference Dropped
  8. 2026-27 Act Not in this version

Pick any two steps to compare their wording.

What changed in the text

House substitute → House passed: the same text in both versions.

HIV Vendor Drug Rebate Funding Loss Replacement. Included in the amounts appropriated above in Strategy A.2.2, HIV/STD Prevention, is $2,300,000 from the General Revenue Fund in fiscal year 2026 and $2,300,000 from the General Revenue Fund in fiscal year 2027 to replace funding from the loss of HIV Vendor Drug Rebates and to maintain funding for the HIV Medication program at the 2024-25 biennium level. Any unexpended and unobligated balances of these funds remaining at the end of the first fiscal year of the biennium are appropriated for the same purposes in the second fiscal year of the biennium.

Removed words are struck through; added words are underlined. Sources: House substitute · House passed.

Every version: numbers, statuses and source pages
VersionRider Against the version beforeAgainst the current budget Source
2024-25 ActGeneral Appropriations Act, 2024-25 Biennium Not in this version
Introduced (Senate)Senate Bill 1 as introduced (LBB recommended, Senate) Not in this version
Introduced (House)House Bill 1 as introduced (LBB recommended, House) Not in this version
Senate substituteCommittee Substitute for Senate Bill 1 Not in this version
House substituteHouse Committee Substitute for Senate Bill 1 37 New New Page II-32
House passedSenate Bill 1 as passed the second house 37 Unchanged New Page II-32
ConferenceConference Committee Report for Senate Bill 1 Not in this version
2026-27 ActGeneral Appropriations Act, 2026-27 Biennium Not in this version
Full text of each wording

House substitute, House passed

Source, page II-32

HIV Vendor Drug Rebate Funding Loss Replacement. Included in the amounts appropriated above in Strategy A.2.2, HIV/STD Prevention, is $2,300,000 from the General Revenue Fund in fiscal year 2026 and $2,300,000 from the General Revenue Fund in fiscal year 2027 to replace funding from the loss of HIV Vendor Drug Rebates and to maintain funding for the HIV Medication program at the 2024-25 biennium level. Any unexpended and unobligated balances of these funds remaining at the end of the first fiscal year of the biennium are appropriated for the same purposes in the second fiscal year of the biennium.